Oroxin B Attenuates Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Formation and Activity

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2021 Dec 8

PMID 34876805

Citations 5

Authors

Jun-Ming Huang

Chen-Zhong Wang

Shun-Yi Lu

Zhe Wang

Zuo-Qin Yan

Affiliations

Soon will be listed here.

Abstract

Background: Osteoclasts are the major players in bone resorption and have always been studied in the prevention and treatment of osteoporosis. Previous studies have confirmed that a variety of flavonoids inhibit osteoporosis and improve bone health mainly through inhibiting osteoclastogenesis. Oroxin B (OB) is a flavonoid compound extracted from traditional Chinese herbal medicine (L.) Vent, exerts potent antitumor and anti-inflammation effect, but its effect on osteoclastogensis remains unknown.

Methods: We comprehensively evaluated the effect of OB on the formation and function of osteoclasts and the underling mechanism by bone marrow-derived macrophage in vitro. In vivo, we used mice ovariectomized model to verify the protective effect of OB.

Results: OB was found to inhibit osteoclast formation and bone resorption function in vitro, in a dose-dependent manner and the increased osteoclastic-related genes induced by RANKL (NFATc1, c-fos, cathepsin K, RANK, MMP9 and TRAP) were also attenuated following OB treatment. Mechanistical investigation showed OB abrogated the increased phosphorylation level of MAPK and NF-κB pathway, and diminished the expression of the vital transcription factors for osteoclastogenesis. OB also prevented ovariectomy (OVX)-induced bone loss by inhibiting osteoclast formation and activity in mice.

Conclusion: Our study demonstrated that OB may act as an anti-osteoporosis agent by inhibiting osteoclast maturation and attenuating bone resorption.

Citing Articles

Caffeine regulates both osteoclast and osteoblast differentiation via the AKT, NF-κB, and MAPK pathways.

Miao Y, Zhao L, Lei S, Zhao C, Wang Q, Tan C Front Pharmacol. 2024; 15:1405173.

PMID: 38939843 PMC: 11208461. DOI: 10.3389/fphar.2024.1405173.

Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent.

Zhou S, Huang J, Chen K, Wang Q, Liu Z, Sun Y Aging (Albany NY). 2024; 16(11):9569-9583.

PMID: 38862240 PMC: 11210224. DOI: 10.18632/aging.205885.

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis.

Huang J, Wang Z, Qi G, Lai Q, Jiang A, Zhang Y Aging (Albany NY). 2023; 15(19):10213-10236.

PMID: 37793008 PMC: 10599742. DOI: 10.18632/aging.205068.

Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy.

Lu R, He Z, Zhang W, Wang Y, Cheng P, Lv Z Front Endocrinol (Lausanne). 2022; 13:1060721.

PMID: 36531454 PMC: 9751055. DOI: 10.3389/fendo.2022.1060721.

The Influence of Different Extraction Techniques on the Chemical Profile and Biological Properties of : Multifunctional Aspects for Potential Pharmaceutical Applications.

Yan K, Cheng X, Bian G, Gao Y, Li D Evid Based Complement Alternat Med. 2022; 2022:8975320.

PMID: 36248411 PMC: 9553467. DOI: 10.1155/2022/8975320.

References

Lee S, Chung W, Kwak H, Chung C, Kwack K, Lee Z . Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem. 2001; 276(52):49343-9. DOI: 10.1074/jbc.M103642200. View

Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J . Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013; 8:137. PMC: 3880492. DOI: 10.1007/s11657-013-0137-0. View

Lalrinzuali K, Vabeiryureilai M, Jagetia G . Topical application of stem bark ethanol extract of Sonapatha, Oroxylum indicum (L.) Kurz accelerates healing of deep dermal excision wound in Swiss albino mice. J Ethnopharmacol. 2018; 227:290-299. DOI: 10.1016/j.jep.2018.08.018. View

Lu L, Rao L, Jia H, Chen J, Lu X, Yang G . Baicalin positively regulates osteoclast function by activating MAPK/Mitf signalling. J Cell Mol Med. 2017; 21(7):1361-1372. PMC: 5487921. DOI: 10.1111/jcmm.13066. View

Kim J, Kim N . Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab. 2014; 21(4):233-41. PMC: 4255043. DOI: 10.11005/jbm.2014.21.4.233. View

Qiu J, Wang D, Zhang Y, Dong J, Wang J, Niu X . Molecular modeling reveals the novel inhibition mechanism and binding mode of three natural compounds to staphylococcal α-hemolysin. PLoS One. 2013; 8(11):e80197. PMC: 3842302. DOI: 10.1371/journal.pone.0080197. View

Zhan Y, Liang J, Tian K, Che Z, Wang Z, Yang X . Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice. Front Pharmacol. 2020; 10:1587. PMC: 6987431. DOI: 10.3389/fphar.2019.01587. View

Abu-Amer Y . NF-κB signaling and bone resorption. Osteoporos Int. 2013; 24(9):2377-86. PMC: 3884829. DOI: 10.1007/s00198-013-2313-x. View

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

10.

Mun S, Park P, Park-Min K . The M-CSF receptor in osteoclasts and beyond. Exp Mol Med. 2020; 52(8):1239-1254. PMC: 8080670. DOI: 10.1038/s12276-020-0484-z. View

11.

Krum S . Direct transcriptional targets of sex steroid hormones in bone. J Cell Biochem. 2011; 112(2):401-8. PMC: 3070194. DOI: 10.1002/jcb.22970. View

12.

Li N, Meng X, Bao Y, Wang S, Li T . Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer. Pharmacogn Mag. 2018; 14(54):207-213. PMC: 5909317. DOI: 10.4103/pm.pm_119_17. View

13.

Edwards J, Mundy G . Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol. 2011; 7(4):235-43. DOI: 10.1038/nrrheum.2011.23. View

14.

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

15.

Lane N . Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194(2 Suppl):S3-11. DOI: 10.1016/j.ajog.2005.08.047. View

16.

Zaveri M, Gohil P, Jain S . Immunostimulant activity of n-butanol fraction of root bark of Oroxylum indicum, vent. J Immunotoxicol. 2008; 3(2):83-99. DOI: 10.1080/15476910600725942. View

17.

Zhang X, Liu T, Huang Y, Wismeijer D, Liu Y . Icariin: does it have an osteoinductive potential for bone tissue engineering?. Phytother Res. 2013; 28(4):498-509. DOI: 10.1002/ptr.5027. View

18.

Huang J, Bao Y, Xiang W, Jing X, Guo J, Yao X . Icariin Regulates the Bidirectional Differentiation of Bone Marrow Mesenchymal Stem Cells through Canonical Wnt Signaling Pathway. Evid Based Complement Alternat Med. 2018; 2017:8085325. PMC: 5763109. DOI: 10.1155/2017/8085325. View

19.

Jiang L, Numonov S, Bobakulov K, Nasimullah Qureshi M, Zhao H, Aisa H . Phytochemical Profiling and Evaluation of Pharmacological Activities of Hypericum scabrum L. Molecules. 2015; 20(6):11257-71. PMC: 6272622. DOI: 10.3390/molecules200611257. View

20.

Chang E, Ha J, Huang H, Kim H, Woo J, Lee Y . The JNK-dependent CaMK pathway restrains the reversion of committed cells during osteoclast differentiation. J Cell Sci. 2008; 121(Pt 15):2555-64. DOI: 10.1242/jcs.028217. View